A Study of LY3493269 in Participants With Type 2 Diabetes
Status:
Completed
Trial end date:
2021-03-04
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine the side effects related to LY3493269 in
participants with type 2 diabetes. Blood tests will be performed to check concentrations of
LY3493269 in the bloodstream. Each enrolled participant will receive LY3493269, dulaglutide,
or placebo. The study will last up to approximately 16 weeks for each participant and may
include up to 11 visits.